Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer

Part of paid clinical trials in Buffalo, New York.

Sponsor: Roswell Park Cancer Institute
Study ID: NCT00107315
Phase: PHASE2
Status: Terminated

Conditions

Colorectal Cancer

Eligibility Criteria

Sex: ALL
Age: 70 Years - N/A
Healthy Volunteers: Not accepted

Interventions

bevacizumab — BIOLOGICAL
capecitabine — DRUG

Study Details

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with capecitabine may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving bevacizumab together with capecitabine works as first-line therapy in treating older patients with metastatic colorectal cancer.